Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech, a developer of RNA interference- (RNAi) and RNA-based therapeutics, has received notice of allowance (NoA) from the US Patent and Trademark Office (USPTO) for its patent application US 11/955,207 covering a library of over 1x10(15) novel peptides.
Subscribe to our email newsletter
The allowance further strengthens the Marina’s nucleic acid-peptide drug delivery platform and expands the patent protection for its comprehensive set of nucleic acid delivery technologies.
The patent application is part of the company’s proprietary Trp Cage Library patent portfolio.
The Trp Cage motif allows to identify peptides with high binding affinity for specific cell or tissue types, and avoids the limitations of low affinity and specificity often associated with linear peptide libraries.
This technology is directly applicable to the company’s DiLA2 and Smarticles delivery platforms as peptides are readily conjugated to the components of these delivery platforms.